- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Vertex Pharmaceuticals Inc
+ Add to WatchlistVRTX:US
78.4300 USD 1.0400 1.31%As of 20:10:00 ET on 05/22/2013.
Snapshot for Vertex Pharmaceuticals Inc (VRTX)
| Open: | 79.4000 | Day's Range: | 77.6700 - 81.4500 | Volume: | 1,446,078 |
|---|---|---|---|---|---|
| Previous Close: | 78.4300 | 52wk Range: | 38.4400 - 87.4700 | 1-Yr Rtn: | +22.66% |
Key Statistics for VRTX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.3254 |
| Est. EPS (USD) (12/2013) | -0.4110 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 17,364.47 |
| Shares Outstanding (M) | 221.40 |
| 30 Day Average Volume | 3,427,473 |
| Price/Book (mrq) | 22.9842 |
| Price/Sale (ttm) | 11.8265 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/30/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for VRTX
Company Profile & Key Executives for VRTX
Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company is developing drugs for the treatment of viral diseases, multidrug resistance in cancer, inflammatory and autoimmune diseases, and neurodegenerative diseases.
| Jeffrey M LeidenChairman/President/CEO | Ian F SmithExec VP/CFO |
| Stuart A ArbuckleExec VP/Chief Commercial Ofcr | Kenneth L Horton "Ken"Exec VP/Chief Legal Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
VRTX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page